Adherex Technologies Q2 Earnings Call Highlights
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.
How this was made
The 30-second read
Why it matters
Traders can update expectations for FENC’s near-term fundamentals using the reported Q2 sales, EBITDA, and cash position, plus management’s 2026 cash operating expense plan and ongoing PEDMARK clinical milestones (including Japan STS-J01).
Market read
Q2 results show strong YoY sales growth and improved adjusted EBITDA, with management outlining a 2026 cash operating expense plan and continued PEDMARK clinical and Japan development progress.
What to watch
Operating expenses rose $3.6M YoY due to headcount and marketing; investors may focus on whether margin expansion persists as commercialization scales and collections timing affects cash.
Background
The piece summarizes Adherex Technologies’ rebranded entity, Fennec Pharmaceuticals, from its Q2 earnings call, focusing on PEDMARK momentum, commercialization, and cash/profitability.
Ticker impact
Fennec reported Q2 net product sales of $17.1M (+78% YoY), $2.8M non-GAAP EBITDA, and $41.2M cash, plus 2026 cash-expense expectations.
Moderate upside bias for FENC on expectations of improving commercialization and funded development, with volatility around any lack of revenue guidance.
The article provides concrete quarterly financials and cash guidance for 2026, but does not add a new regulatory/approval milestone or quantified revenue outlook beyond cash operating expense framing.
Market effects
Biopharma investors may read the PEDMARK commercialization and cash runway as a positive signal for ototoxicity-prevention oncology assets.
Japan STS-J01 oral presentation selection may support Asia-Pacific development sentiment for similar supportive-care oncology programs.
Conference lead-generation and investigator-study updates reinforce global clinical momentum, but without a new approval catalyst.
Counterpoint
Despite strong YoY sales growth, management did not provide a quantitative revenue outlook, so the market may discount sustainability of the run-rate.
Key entities
- companyFennec Pharmaceuticals Inc
NASDAQ-listed biopharma developing PEDMARK for cisplatin-induced hearing loss prevention; reported Q2 financials and provided 2026 cash-expense expectations.
- product_candidatePEDMARK
Lead candidate discussed across commercialization metrics, investigator-sponsored studies, and a Japan trial (STS-J01) selected for an oral presentation.
- research_institutionUniversity of Arizona Cancer Center
Site for a third investigator-sponsored study evaluating PEDMARK in AYA and adult head-and-neck and testicular cancers.
- clinical_trialSTS-J01
Japan investigator-initiated Phase II/III trial selected for an oral presentation at SIOP 2026, including first public human PK data.
